Mark Pollack to Piperazines
This is a "connection" page, showing publications Mark Pollack has written about Piperazines.
Connection Strength
1.539
-
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012; 81(2):87-97.
Score: 0.394
-
Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011 Jul; 72(7):892-7.
Score: 0.369
-
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008 May; 65(5):551-62.
Score: 0.304
-
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
Score: 0.096
-
RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010 Oct; 16(5):322-5.
Score: 0.090
-
Refractory generalized anxiety disorder. J Clin Psychiatry. 2009; 70 Suppl 2:32-8.
Score: 0.080
-
Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008 Jun; 13(6):522-7.
Score: 0.076
-
Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005 Jan; 20(1):9-11.
Score: 0.060
-
Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998; 8(3):131-3.
Score: 0.037
-
Treatment of dysphoric mania with nefazodone. Am J Psychiatry. 1996 May; 153(5):732-3.
Score: 0.033